Botox Treatment for Patients with Hidradenitis Suppurativa: A Within-Person, Randomized, Double-blind, Controlled Study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519946-54-00

Enrollment

Registered

2025-02-25

Start date

2025-04-01

Completion date

Unknown

Last updated

2025-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hidradenitis Suppurativa

Brief summary

Reduction in IHS4 score

Detailed description

1. Reduction in number of inflammatory nodules, non-inflammatory nodules and draining tunnels. 2. High treatment satisfaction (NRS 0-10). 3. HiSCR50 achieved. 4. Reduction of HiSQOL. 5. DLQI reduction. 6. Pain reduction. 7. Suppuration reduction. 8. Pruritis reduction. 9. Reduction in patient reported disease severity. 10. If the patient would recommend the treatment to others

Interventions

DRUGNatriumklorid isotonisk "SAD"

DRUGinjektionsvæske

DRUGopløsning

DRUGDysport

DRUGpulver til injektionsvæske

DRUGopløsning 300 enheder

DRUGXEOMIN 100 units powder for solution for injection

DRUGBOTOX

DRUGopløsning 100 Allergan-enheder

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Reduction in IHS4 score	—

Secondary

Measure	Time frame
1. Reduction in number of inflammatory nodules, non-inflammatory nodules and draining tunnels. 2. High treatment satisfaction (NRS 0-10). 3. HiSCR50 achieved. 4. Reduction of HiSQOL. 5. DLQI reduction. 6. Pain reduction. 7. Suppuration reduction. 8. Pruritis reduction. 9. Reduction in patient reported disease severity. 10. If the patient would recommend the treatment to others	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026